

WEST Search History

DATE: Wednesday, April 26, 2006

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
	<i>DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L43	L42 not @py>2000	4
<input type="checkbox"/>	L42	L41 and l5	37
<input type="checkbox"/>	L41	L40 and l19	144
<input type="checkbox"/>	L40	L39 or l38	11348
<input type="checkbox"/>	L39	(514/1,2,423)![CCLS]	10290
<input type="checkbox"/>	L38	(424/134.1,144.1)![CCLS]	1142
<input type="checkbox"/>	L37	L36 and human	1
<input type="checkbox"/>	L36	5444069.pn.	1
<input type="checkbox"/>	L35	L34 and l5	5
<input type="checkbox"/>	L34	L33 and l25	5
<input type="checkbox"/>	L33	(suthanthiran or maluccio).in.	18
<input type="checkbox"/>	L32	L31 and losartan	1
<input type="checkbox"/>	L31	L30 and l5	1
<input type="checkbox"/>	L30	5824696.pn.	1
<input type="checkbox"/>	L29	L28 and L21	14
<input type="checkbox"/>	L28	L27 not @py>=2000	15
<input type="checkbox"/>	L27	L26 and L5	88
<input type="checkbox"/>	L26	L25.ab.	1053
<input type="checkbox"/>	L25	angiotensin II	7328
<input type="checkbox"/>	L24	L22 not @py>2000	80
<input type="checkbox"/>	L23	L22 not @ay>2000	119
<input type="checkbox"/>	L22	L21 and L20	272
<input type="checkbox"/>	L21	antagoni\$ or inhibit\$	665630
<input type="checkbox"/>	L20	L18 and L19	286
<input type="checkbox"/>	L19	L16.ab.	1946
<input type="checkbox"/>	L18	L5 or L6	232985
<input type="checkbox"/>	L17	L16 and L5	7934
<input type="checkbox"/>	L16	angiotensin\$	15420
<input type="checkbox"/>	L15	L6 and L13	0
<input type="checkbox"/>	L14	L5 and L13	0

<input type="checkbox"/>	L13	L12 or L11 or L10	31
<input type="checkbox"/>	L12	(5034512 or 4894437 or 5098924 or 5055466 or 4885292 or 5075451 or 4980283 or 5066643).pn.	8
<input type="checkbox"/>	L11	(5114937 or 5106835 or 5063208 or 4845079 or 4845079 or 5089471 or 5071837 or 5064965 or 5063207 or 5036054 or 5036053).pn.	10
<input type="checkbox"/>	L10	(4168267 or 4337201 or 5256687 or 4316906 or 5589499 or 4452740 or 4432970 or 5116835 or 5095119 or 5104869).pn.	13
<input type="checkbox"/>	L9	L4 and L6	1
<input type="checkbox"/>	L8	L5 and L4	1
<input type="checkbox"/>	L7	L5 and L4	0
<input type="checkbox"/>	L6	angiogen\$ or neovascu\$ or prolifer\$	119958
<input type="checkbox"/>	L5	cancer\$ or tumor\$ or neoplas\$	187735
<input type="checkbox"/>	L4	L3 or L2 or L1	21
<input type="checkbox"/>	L3	4508729.pn.	1
<input type="checkbox"/>	L2	(4316906 or 4374829 or 4344949 or 450879 or 4587256 or 5045553 or 4410520 or 4512924).pn.	9
<input type="checkbox"/>	L1	(5608075 or 5087643 or 6004989 or 6001881 or 598884 or 5234581 or 5889020 or 4473575 or 4105776).pn.	11

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6

DICTIONARY FILE UPDATES: 25 APR 2006 HIGHEST RN 881879-55-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> E "LOSARTAN"/CN 25

E1 1 LOSAN/CN

E2 1 LOSANTIN/CN

E3 1 --> LOSARTAN/CN

E4 1 LOSARTAN MONOPOTASSIUM SALT/CN

E5 1 LOSARTAN P-TOLUENESULFONATE/CN

E6 1 LOSARTAN POTASSIUM/CN

E7 1 LOSARTAN-HYDROCHLOROTHIAZIDE MIXT./CN

E8 1 LOSBANINE/CN

E9 1 LOSE-URONATE KETOL-ISOMERASE (YERSINIA PESTIS STRAIN CO92 GENE KDUI)/CN

E10 1 LOSEC/CN

E11	1	LOSEC SODIUM/CN
E12	1	LOSEYITE/CN
E13	1	LOSFERRON/CN
E14	1	LOSIGAMONE/CN
E15	1	LOSIL 1000-50/CN
E16	1	LOSIL 1000-65/CN
E17	1	LOSIL 800-50/CN
E18	1	LOSIL 800-65/CN
E19	1	LOSINDOLE/CN
E20	1	LOSK/CN
E21	1	LOSMIPROFEN/CN
E22	1	LOSO PREP/CN
E23	1	LOSOL BLUE/CN
E24	1	LOSOXANTRONE/CN
E25	1	LOSOXANTRONE HYDROCHLORIDE/CN

=> S E3

L1 1 LOSARTAN/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN

RN 114798-26-4 REGISTRY

CN 1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN DUP 89

CN Lortaan

CN **Losartan**

FS 3D CONCORD

MF C22 H23 Cl N6 O

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, MEDLINE, MRCK*, PATDPASPC, PROMT, PROUSDDR, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Other Sources: WHO


DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2404 REFERENCES IN FILE CA (1907 TO DATE)
 31 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2414 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> E "ENALAPRIL"/CN 25

E1	1	ENALADIL/CN
E2	1	ENALAPRAT/CN
E3	1 -->	ENALAPRIL/CN
E4	1	ENALAPRIL ACETATE/CN
E5	1	ENALAPRIL ACID/CN
E6	1	ENALAPRIL BENZYL ESTER/CN
E7	1	ENALAPRIL CALCIUM DIHYDRATE/CN
E8	1	ENALAPRIL DIACID/CN
E9	1	ENALAPRIL DIKETOPIPERAZINE/CN
E10	1	ENALAPRIL DKP/CN
E11	1	ENALAPRIL HYDROCHLORIDE/CN
E12	1	ENALAPRIL MALEATE/CN
E13	1	ENALAPRIL MALEATE-HYDROCHLOROTHIAZIDE MIXT./CN
E14	1	ENALAPRIL SODIUM/CN
E15	1	ENALAPRIL TERT-BUTYL ESTER/CN
E16	1	ENALAPRIL-KETANSERIN MIXT./CN
E17	1	ENALAPRILAT/CN
E18	1	ENALAPRILAT SRS/CN
E19	1	ENALAPRILAT-KETANSERIN MIXT./CN
E20	1	ENALAPRILATE/CN
E21	1	ENALAPRILIC ACID/CN
E22	1	ENALIN A/CN
E23	1	ENALIN B/CN
E24	1	ENALITE/CN
E25	1	ENALKIREN/CN

=> S E3

L2 1 ENALAPRIL/CN

=> DIS L2 1 RN

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 75847-73-3 REGISTRY

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.51

12.72

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 25 Apr 2006 (20060425/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 11 or 12

2414 L1

2695 L2

L3 4684 L1 OR L2

=> s cancer? or tumor? or neoplas?

290705 CANCER?

425403 TUMOR?

446494 NEOPLAS?

L4 704495 CANCER? OR TUMOR? OR NEOPLAS?

=> s 14 and 13

L5 146 L4 AND L3

=> s 13 (L) 14

L6 22 L3 (L) L4

=> s 16 not py>2000

5711376 PY>2000

L7 3 L6 NOT PY>2000

=> d ibib 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:794097 CAPLUS

DOCUMENT NUMBER: 132:18639

TITLE: Do ACE-inhibitors suppress tumor necrosis
factor- α production in advanced chronic renal
failure?

AUTHOR(S): Stenvinkel, P.; Andersson, P.; Wang, T.; Lindholm, B.;
Bergstrom, J.; Palmblad, J.; Heimbürger, O.;
Cederholm, T.

CORPORATE SOURCE: Departments of Clinical Science, Divisions of Renal
Medicine and Baxter Novum, Stockholm, Swed.

SOURCE: Journal of Internal Medicine (1999), 246(5), 503-507
CODEN: JINMEO; ISSN: 0954-6820

PUBLISHER: Blackwell Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:688629 CAPLUS
 DOCUMENT NUMBER: 132:175414
 TITLE: Pharmacological modifications of the partial pressure
 of oxygen in murine tumors: evaluation using in vivo
 EPR oximetry
 AUTHOR(S): Gallez, Bernard; Jordan, Benedicte F.; Baudelet,
 Christine; Misson, Pierre-Damien
 CORPORATE SOURCE: Laboratory of Medicinal Chemistry and Radiopharmacy,
 Universite Catholique de Louvain, Brussels, Belg.
 SOURCE: Magnetic Resonance in Medicine (1999), 42(4), 627-630
 CODEN: MRMEEN; ISSN: 0740-3194
 PUBLISHER: Wiley-Liss, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:845231 CAPLUS
 DOCUMENT NUMBER: 123:275949
 TITLE: Angiotensin-converting-enzyme inhibitors suppress
 synthesis of tumor necrosis factor and interleukin 1
 by human peripheral blood mononuclear cells
 AUTHOR(S): Schindler, Ralf; Dinarello, Charles A.; Koch, Karl-M.
 CORPORATE SOURCE: Department of Nephrology, Medical School Hannover,
 Berlin, D-14050, Germany
 SOURCE: Cytokine (1995), 7(6), 526-33
 CODEN: CYTIE9; ISSN: 1043-4666
 PUBLISHER: Academic
 DOCUMENT TYPE: Journal
 LANGUAGE: English

=> d ibibi abs 2
 'IBIBI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
 ALL ----- BIB, AB, IND, RE
 APPS ----- AI, PRAI
 BIB ----- AN, plus Bibliographic Data and PI table (default)
 CAN ----- List of CA abstract numbers without answer numbers
 CBIB ----- AN, plus Compressed Bibliographic Data
 CLASS ----- IPC, NCL, ECLA, FTERM
 DALL ----- ALL, delimited (end of each field identified)
 DMAX ----- MAX, delimited for post-processing
 FAM ----- AN, PI and PRAI in table, plus Patent Family data
 FBIB ----- AN, BIB, plus Patent FAM
 IND ----- Indexing data
 IPC ----- International Patent Classifications
 MAX ----- ALL, plus Patent FAM, RE
 PATS ----- PI, SO
 SAM ----- CC, SX, TI, ST, IT
 SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
 SCAN must be entered on the same line as the DISPLAY,
 e.g., D SCAN or DISPLAY SCAN)
 STD ----- BIB, CLASS
 IABS ----- ABS, indented with text labels
 IALL ----- ALL, indented with text labels
 IBIB ----- BIB, indented with text labels

IMAX ----- MAX, indented with text labels
 ISTD ----- STD, indented with text labels

 OBIB ----- AN, plus Bibliographic Data (original)
 OIBIB ----- OBIB, indented with text labels

 SBIB ----- BIB, no citations
 SIBIB ----- IBIB, no citations

 HIT ----- Fields containing hit terms
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
 containing hit terms
 HITRN ----- HIT RN and its text modification
 HITSTR ----- HIT RN, its text modification, its CA index name, and
 its structure diagram
 HITSEQ ----- HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and
 its structure diagram
 FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
 structure diagram, plus NTE and SEQ fields
 KWIC ----- Hit term plus 20 words on either side
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.
 ENTER DISPLAY FORMAT (BIB):ibib

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:688629 CAPLUS
 DOCUMENT NUMBER: 132:175414
 TITLE: Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry
 AUTHOR(S): Gallez, Bernard; Jordan, Benedicte F.; Baudalet, Christine; Misson, Pierre-Damien
 CORPORATE SOURCE: Laboratory of Medicinal Chemistry and Radiopharmacy, Universite Catholique de Louvain, Brussels, Belg.
 SOURCE: Magnetic Resonance in Medicine (1999), 42(4), 627-630
 CODEN: MRMEEN; ISSN: 0740-3194
 PUBLISHER: Wiley-Liss, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs 2

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:688629 CAPLUS
 DOCUMENT NUMBER: 132:175414
 TITLE: Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry

AUTHOR(S): Gallez, Bernard; Jordan, Benedicte F.; Baudalet, Christine; Misson, Pierre-Damien
CORPORATE SOURCE: Laboratory of Medicinal Chemistry and Radiopharmacy, Universite Catholique de Louvain, Brussels, Belg.
SOURCE: Magnetic Resonance in Medicine (1999), 42(4), 627-630
CODEN: MRMEEN; ISSN: 0740-3194
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB EPR oximetry using an implantable paramagnetic probe was used to quantify the partial pressure of O (pO₂) in tissues in a transplantable mouse tumor model after administration of 34 different vasodilators belonging to one of the following classes: angiotensin-converting enzyme inhibitors, Ca²⁺ antagonists, α -antagonists, K⁺ channel openers, β -blockers, NO donors, and peripheral vasoactive agents. Twenty-four compds. were efficient in significantly increasing the local pO₂ in a majority of tumors. The increase of local pO₂ by the pharmacol. treatments was lower than that achieved by using O or carbogen breathing. This technique offers a tool for rapidly and accurately measuring treatment-induced modifications of pO₂ in tumors.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s prolif? or angiogen? or neovascular?

240616 PROLIF?

35334 ANGIOGEN?

7034 NEOVASCULAR?

L8 266785 PROLIF? OR ANGIOGEN? OR NEOVASCULAR?

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

E "LOSARTAN"/CN 25

L1 1 S E3

E "ENALAPRIL"/CN 25

L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

L3 4684 S L1 OR L2

L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?

L5 146 S L4 AND L3

L6 22 S L3 (L) L4

L7 3 S L6 NOT PY>2000

L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?

=> s 18 and 13

L9 220 L8 AND L3

=> s 18 (1) 13

L10 46 L8 (L) L3

=> s 110 not py>2000

5711376 PY>2000

L11 18 L10 NOT PY>2000

=> d ibib 1-6

L11 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:23055 CAPLUS

DOCUMENT NUMBER: 134:161364

TITLE: Retinal neovascularization is prevented by blockade of the renin-angiotensin system
 AUTHOR(S): Moravski, Christina J.; Kelly, Darren J.; Cooper, Mark E.; Gilbert, Richard E.; Bertram, John F.; Shahinfar, Shahnaz; Skinner, Sandford L.; Wilkinson-Berka, Jennifer L.
 CORPORATE SOURCE: Department of Physiology, The University of Melbourne, Parkville, 3010, Australia
 SOURCE: Hypertension (2000), 36(6), 1099-1104
 CODEN: HPRTDN; ISSN: 0194-911X
 PUBLISHER: Lippincott Williams & Wilkins
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:871260 CAPLUS
 DOCUMENT NUMBER: 135:322
 TITLE: The effect of losartan on intimal thickening in rats after vascular balloon injury
 AUTHOR(S): Li, Yonghong; Dong, Guoxiong; Guo, Minglei
 CORPORATE SOURCE: Department of Emergency, The Affiliated Hospital of Qingdao University Medical College, Tsingtao, 266003, Peop. Rep. China
 SOURCE: Qingdao Daxue Yixueyuan Xuebao (2000), 36(4), 271-273
 CODEN: QDYXAE
 PUBLISHER: Qingdao Daxue Yixueyuan Xuebao Bianjibu
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

L11 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:808012 CAPLUS
 DOCUMENT NUMBER: 134:290166
 TITLE: Antagonistic effect of monocyte chemotactic protein-1 monoclonal antibody and losartan on proliferation and migration of Ang-II-mediated VSMCs in vitro
 AUTHOR(S): He, Zuo-yun; Li, Ai-min
 CORPORATE SOURCE: Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chungking, 400037, Peop. Rep. China
 SOURCE: Di-San Junyi Daxue Xuebao (2000), 22(9), 815-818
 CODEN: DYXUE8; ISSN: 1000-5404
 PUBLISHER: Di-San Junyi Daxue
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

L11 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:413731 CAPLUS
 DOCUMENT NUMBER: 133:246971
 TITLE: The stimulating effects of neuropeptide Y on cultured arterial smooth muscle cell proliferation and losartan treatment
 AUTHOR(S): Huang, Shao-Hua; Liu, Jian-Kang; Chen, Min-Sheng
 CORPORATE SOURCE: First Affiliated Hospital, Guangzhou Medical College, Canton, 510182, Peop. Rep. China
 SOURCE: Zhongguo Bingli Shengli Zazhi (2000), 16(3), 211-213
 CODEN: ZBSZEB; ISSN: 1000-4718
 PUBLISHER: Jinan Daxue
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese

L11 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:307168 CAPLUS
 DOCUMENT NUMBER: 133:187796
 TITLE: Enalapril inhibits growth and proliferation of various tissues in rat normotensive four-sixths kidney ablation nephropathy
 AUTHOR(S): Gajdos, Martin; Krivosikova, Zora; Sebekova, Katarina; Lajdova, Ingrid; Spustova, Viera; Dzurik, Rastislav
 CORPORATE SOURCE: Institute of Preventive and Clinical Medicine, Bratislava, 833 01, Slovakia
 SOURCE: Kidney & Blood Pressure Research (2000), 23(2), 106-112
 CODEN: KBPRFC; ISSN: 1420-4096
 PUBLISHER: S. Karger AG
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:52976 CAPLUS
 DOCUMENT NUMBER: 132:329674
 TITLE: Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat
 AUTHOR(S): Krivosikova, Z.; Sebekova, K.; Spustova, V.; Lajdova, I.; Dzurik, R.
 CORPORATE SOURCE: Institute of Preventive and Clinical Medicine, Bratislava, Slovakia
 SOURCE: Physiological Research (Prague) (1999), 48(6), 429-435.
 CODEN: PHRSEJ; ISSN: 0862-8408
 PUBLISHER: Institute of Physiology, Academy of Sciences of the Czech Republic
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib 7-12

L11 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2000:14644 CAPLUS
 DOCUMENT NUMBER: 132:288508
 TITLE: Smooth muscle cell proliferation in the ductus arteriosus and the descending aorta, and effects of enalapril on SMC proliferation in perinatal rats
 AUTHOR(S): Takizawa, Tatsuya; Kawahata, Mariko; Ikeda, Yoshinori; Yamamoto, Masako; Arishima, Kazuyoshi; Muto, Makoto; Masaoka, Toshio
 CORPORATE SOURCE: Departments of Developmental and Reproductive Biotechnology, Azabu University School of Veterinary Medicine, Sagami-hara, 229-8501, Japan
 SOURCE: Journal of Veterinary Medical Science (1999), 61(11), 1215-1218
 CODEN: JVMSEQ; ISSN: 0916-7250
 PUBLISHER: Japanese Society of Veterinary Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:649604 CAPLUS

DOCUMENT NUMBER: 132:178991
TITLE: Effect of angiotensin II receptor antagonist on proliferation of glomerular mesangial cells from spontaneously hypertensive rats
AUTHOR(S): Chen, Shaoxing; Guo, Jizhen; Qiang, Weiguo; Du, Jian; Liu, Xiaoping; Zhu, Dingliang
CORPORATE SOURCE: Department of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Second Medical University, Shanghai, 200025, Peop. Rep. China
SOURCE: Shanghai Dier Yike Daxue Xuebao (1999), 19(4), 292-294
CODEN: SDDXE3; ISSN: 0258-5898
PUBLISHER: Shanghai Dier Yike Daxue Xuebao Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

L11 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:360095 CAPLUS
DOCUMENT NUMBER: 131:179549
TITLE: Angiotensin II receptor antagonists prevent neointimal proliferation in a porcine coronary artery organ culture model
AUTHOR(S): Wilson, David P.; Saward, Laura; Zahradka, Peter; Kee Cheung, Po
CORPORATE SOURCE: Department of Physiology, University of Manitoba, MB, Can.
SOURCE: Cardiovascular Research (1999), 42(3), 761-772
CODEN: CVREAU; ISSN: 0008-6363
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:306644 CAPLUS
DOCUMENT NUMBER: 131:68521
TITLE: Effects of TH-142177 on angiotensin II-induced proliferation, migration and intracellular signaling in vascular smooth muscle cells and on neointimal thickening after balloon injury
AUTHOR(S): Nozawa, Yoshihisa; Matsuura, Naosuke; Miyake, Hidekazu; Yamada, Shizuo; Kimura, Ryohei
CORPORATE SOURCE: Pharmacology Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, 771-0194, Japan
SOURCE: Life Sciences (1999), 64(22), 2061-2070
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:284031 CAPLUS
DOCUMENT NUMBER: 129:36278
TITLE: Divergent effects of angiotensin-converting enzyme inhibition and angiotensin II-receptor antagonism on myocardial cellular proliferation and collagen deposition after myocardial infarction in rats
AUTHOR(S): Taylor, Kenneth; Patten, Richard D.; Smith, John J.; Aronovitz, Mark J.; Wight, Joseph; Salomon, Robert N.; Konstam, Marvin A.
CORPORATE SOURCE: Division of Cardiology, Department of Medicine, New

England Medical Center, Tufts University School of
Medicine, Boston, MA, 02111, USA
SOURCE: Journal of Cardiovascular Pharmacology (1998), 31(5),
654-660
CODEN: JCPCDT; ISSN: 0160-2446
PUBLISHER: Lippincott-Raven Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:108045 CAPLUS
DOCUMENT NUMBER: 126:195036
TITLE: In vitro and in vivo effects of UP 269-6, a new potent
orally active nonpeptide angiotensin II receptor
antagonist, on vascular smooth muscle cell
proliferation
AUTHOR(S): Virone-Oddos, A.; Desangle, V.; Provost, D.; Cazes,
M.; Caussade, F.; Cloarec, A.
CORPORATE SOURCE: Lab. UPSA, Rueil-Malmaison, 92506, Fr.
SOURCE: British Journal of Pharmacology (1997), 120(3),
488-494
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Stockton
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

E "LOSARTAN"/CN 25
L1 1 S E3
E "ENALAPRIL"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

L3 4684 S L1 OR L2
L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5 146 S L4 AND L3
L6 22 S L3 (L) L4
L7 3 S L6 NOT PY>2000
L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9 220 S L8 AND L3
L10 46 S L8 (L) L3
L11 18 S L10 NOT PY>2000

=> s l10 and l4

L12 7 L10 AND L4

=> d ibib 1-7

L12 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:182557 CAPLUS
DOCUMENT NUMBER: 144:267234
TITLE: Effects of angiotensin II receptor antagonist,
Losartan on the apoptosis, proliferation and migration
of the human pancreatic stellate cells
AUTHOR(S): Liu, Wen-Bin; Wang, Xing-Peng; Wu, Kai; Zhang, Ru-Ling
CORPORATE SOURCE: Shanghai No. 1 People's Hospital, Shanghai Jiaotong

SOURCE: University, Shanghai, 200080, Peop. Rep. China
World Journal of Gastroenterology (2005), 11(41),
6489-6494
CODEN: WJGAF2; ISSN: 1007-9327
PUBLISHER: World Journal of Gastroenterology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:577447 CAPLUS
DOCUMENT NUMBER: 143:379379
TITLE: Effects of Combined Endothelin and Angiotensin II
Antagonism on Growth Factor-Induced Proliferation of
Vascular Smooth Muscle Cells Isolated from Uremic Rats
AUTHOR(S): Wolf, Sabine; Sauter, Gabriele; Risler, Teut; Brehm,
Bernhard
CORPORATE SOURCE: Medical Clinic IV, Department of Hypertension and
Renal Failure and Endocrinology, University of
Tuebingen, Tuebingen, Germany
SOURCE: Renal Failure (2005), 27(4), 465-474
CODEN: REFAE8; ISSN: 0886-022X
PUBLISHER: Taylor & Francis, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:291659 CAPLUS
DOCUMENT NUMBER: 143:323408
TITLE: Blockage of angiotensin II type I receptor decreases
the synthesis of growth factors and induces apoptosis
in C6 cultured cells and C6 rat glioma
AUTHOR(S): Arrieta, O.; Guevara, P.; Escobar, E.;
Garcia-Navarrete, R.; Pineda, B.; Sotelo, J.
CORPORATE SOURCE: Neuroimmunology Unit of the National Institute of
Neurology and Neurosurgery of Mexico, Mexico City,
14269, Mex.
SOURCE: British Journal of Cancer (2005), 92(7), 1247-1252
CODEN: BJCAAI; ISSN: 0007-0920
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:88914 CAPLUS
DOCUMENT NUMBER: 142:403819
TITLE: Influence of growth factors on the proliferation of
vascular smooth muscle cells isolated from subtotaly
nephrectomized rats after endothelin or angiotensin II
antagonism
AUTHOR(S): Wolf, Sabine C.; Sauter, Gabriele; Rodemann,
Hans-Peter; Risler, Teut; Brehm, Bernhard R.
CORPORATE SOURCE: Medical Clinic III, Department of Cardiology,
Nephrology, Hypertension and Renal Failure,
Eberhard-Karls-University, Tuebingen, D-72076, Germany
SOURCE: Nephrology, Dialysis, Transplantation (2005), 20(2),
312-318
CODEN: NDTREA; ISSN: 0931-0509

PUBLISHER: Oxford University Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:777526 CAPLUS
DOCUMENT NUMBER: 139:286322
TITLE: PAR receptor-mediated antiangiogenic activity of thrombin and use of PAR receptor agonists for the treatment of **cancer** and other angiogenesis-associated diseases
INVENTOR(S): Sukhatme, Vikas P.; Merchan, Jaime; Chan, Barden
PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003079978	A2	20031002	WO 2003-US8121	20030314
WO 2003079978	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003218213	A1	20031008	AU 2003-218213	20030314
US 2005232925	A1	20051020	US 2005-508317	20050616
PRIORITY APPLN. INFO.:			US 2002-365165P	P 20020318
			WO 2003-US8121	W 20030314

L12 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:272945 CAPLUS
DOCUMENT NUMBER: 139:301459
TITLE: The effect of commonly used drugs on angiogenesis
AUTHOR(S): Sartippour, Maryam R.; De Leon, Ernesto; Rubio, Rosalio; Brooks, Mai N.
CORPORATE SOURCE: Department of Surgery, Division of Oncology, University of California, Los Angeles, CA, 90095, USA
SOURCE: Anticancer Research (2003), 23(1A), 231-234
CODEN: ANTRD4; ISSN: 0250-7005
PUBLISHER: International Institute of Anticancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:14362 CAPLUS
DOCUMENT NUMBER: 136:379590
TITLE: AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma
AUTHOR(S): Rivera, E.; Arrieta, O.; Guevara, P.; Duarte-Rojo, A.;

CORPORATE SOURCE: Sotelo, J.
 and Neuroimmunology Unit, National Institute of Neurology
 and Neurosurgery of Mexico, Mexico, 14269, Mex.
 SOURCE: British Journal of Cancer (2001), 85(9), 1396-1399
 CODEN: BJCAAI; ISSN: 0007-0920
 PUBLISHER: Harcourt Publishers Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s losartan or enalapril
 4562 LOSARTAN
 1 LOSARTANS
 4562 LOSARTAN
 (LOSARTAN OR LOSARTANS)
 3733 ENALAPRIL
 L13 7727 LOSARTAN OR ENALAPRIL

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

E "LOSARTAN"/CN 25
 L1 1 S E3
 E "ENALAPRIL"/CN 25
 L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

L3 4684 S L1 OR L2
 L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?
 L5 146 S L4 AND L3
 L6 22 S L3 (L) L4
 L7 3 S L6 NOT PY>2000
 L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
 L9 220 S L8 AND L3
 L10 46 S L8 (L) L3
 L11 18 S L10 NOT PY>2000
 L12 7 S L10 AND L4
 L13 7727 S LOSARTAN OR ENALAPRIL

=> s l13 (1) l4
 L14 92 L13 (L) L4

=> s l14 not py>2000
 5711376 PY>2000
 L15 28 L14 NOT PY>2000

=> s l14 not py>1999
 6603140 PY>1999
 L16 23 L14 NOT PY>1999

=> s l16 and l8
 L17 4 L16 AND L8

=> d ibib 1-4

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1998:204801 CAPLUS

DOCUMENT NUMBER: 128:304377

TITLE: Angiotensin II-induced Ca²⁺ mobilization and prolactin

release in normal and hyperplastic pituitary cells
 AUTHOR(S): Diaz-Torga, Graciela; Gonzelez Iglesias, Arturo;
 Achaval-Zaia, Rita; Libertun, Carlos; Becu-Villalobos,
 Damasia
 CORPORATE SOURCE: Inst. Biologia Medicina Experimental, Consejo
 Investigaciones Cientificas Tecnicas, Buenos Aires,
 1428, Argent.
 SOURCE: American Journal of Physiology (1998), 274(3, Pt. 1),
 E534-E540
 CODEN: AJPHAP; ISSN: 0002-9513
 PUBLISHER: American Physiological Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997:256278 CAPLUS
 DOCUMENT NUMBER: 126:329068
 TITLE: Sequential development of angiotensin receptors and
 angiotensin I converting enzyme during
angiogenesis in the rat subcutaneous sponge
 granuloma
 AUTHOR(S): Walsh, David A.; Hu, De-En; Wharton, John; Catravas,
 John D.; Blake, David R.; Fan, Tai-Ping D.
 CORPORATE SOURCE: Inflammation Group, London Hospital Medical College,
 London, E1 2AD, UK
 SOURCE: British Journal of Pharmacology (1997), 120(7),
 1302-1311
 CODEN: BJPCBM; ISSN: 0007-1188
 PUBLISHER: Stockton
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:939339 CAPLUS
 DOCUMENT NUMBER: 124:52845
 TITLE: Is estrogen-induced pituitary hyperplasia and
 hyperprolactinemia mediated by angiotensin II?
 AUTHOR(S): Pawlikowski, M.; Mucha, S.; Kunert-Radek, J.; Sepien,
 H.; Pisarek, H.; Stawowy, A.
 CORPORATE SOURCE: Institute Endocrinology, Medical University Lodz,
 Lodz, Pol.
 SOURCE: Advances in Experimental Medicine and Biology (1995),
 377(Tissue Renin-Angiotensin Systems), 371-8
 CODEN: AEMBAP; ISSN: 0065-2598
 PUBLISHER: Plenum
 DOCUMENT TYPE: Journal
 LANGUAGE: English

L17 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1995:845231 CAPLUS
 DOCUMENT NUMBER: 123:275949
 TITLE: Angiotensin-converting-enzyme inhibitors suppress
 synthesis of tumor necrosis factor and interleukin 1
 by human peripheral blood mononuclear cells
 AUTHOR(S): Schindler, Ralf; Dinarello, Charles A.; Koch, Karl-M.
 CORPORATE SOURCE: Department of Nephrology, Medical School Hannover,
 Berlin, D-14050, Germany
 SOURCE: Cytokine (1995), 7(6), 526-33
 CODEN: CYTIE9; ISSN: 1043-4666
 PUBLISHER: Academic
 DOCUMENT TYPE: Journal

LANGUAGE: English

=> d kwic 1-2

L17 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AB . . . on prolactin release, intracellular calcium ($[Ca^{2+}]_i$) mobilization, and $[3H]$ thymidine uptake in cells from normal rat pituitaries and from estrogen-induced pituitary **tumors**. ANG II (10^{-7} to 10^{-9} M) increased prolactin release significantly in control and not in **tumoral** cells. In control cells, ANG II (10^{-6} to 10^{-9} M) produced an immediate spike of $[Ca^{2+}]_i$ followed by a plateau. . . . significantly between 10^{-10} and 10^{-8} M ANG II, whereas the onset of the spike was retarded with decreasing concns. In **tumoral** cells, ANG II did not produce a spike phase even at 10^{-6} M. ANG II-induced prolactin release and calcium mobilization were blocked by **losartan** (AT1 receptor antagonist) and not by PD-123319 (AT2 antagonist). Finally, $[3H]$ thymidine uptake was not modified by ANG II (10^{-7} to. . . . estrogenic treatment alters in vitro pituitary response to ANG II. Alterations might function to limit excessive prolactin secretion of hypersecreting **tumors**. Besides, ANG II does not modify DNA synthesis in vitro of cells from normal or **tumor**-derived hypophyses.

IT Cell **proliferation**

Pituitary gland

(angiotensin II-induced Ca^{2+} mobilization and prolactin release in normal and hyperplastic pituitary cells)

L17 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

TI Sequential development of angiotensin receptors and angiotensin I converting enzyme during **angiogenesis** in the rat subcutaneous sponge granuloma

AB The vasoconstrictor peptide angiotensin II (AII) can stimulate **angiogenesis**, an important process in wound healing, **tumor** growth and chronic inflammation. To elucidate mechanisms underlying AII-enhanced **angiogenesis**, we have studied a s.c. sponge granuloma model in the rat by use of ^{133}Xe clearance, morphometry and quant. in. . . . directly into the sponge, AII (1 nmol day^{-1}) increased ^{133}Xe clearance from, and fibrovascular growth in sponge granulomas, indicating enhanced **angiogenesis** 6 to 12 days after implantation. This AII-enhanced **angiogenesis** was inhibited by daily doses (100 nmol/sponge) of the specific but subtype non-selective AII receptor antagonist (Sar1, Ile8)AII, and by the selective non-peptide AT1 receptor antagonists **losartan** and DuP 532. In contrast, AII-enhanced **neovascularization** was not inhibited by the AT2 receptor antagonist PD123319, nor was it mimicked by the AT2 receptor agonist CGP42112A (each. . . . (ACE) inhibitors captopril (up to $100\text{ }\mu\text{g/sponge day}^{-1}$) and lisinopril ($40\text{ }\mu\text{g/sponge day}^{-1}$), or AII receptor antagonists did not affect **angiogenesis** in the absence of exogenous AII. $[^{125}I]$ -(Sar1, Ile8)AII binding sites with characteristics of AT1 receptors were localized to microvessels and. . . . days after sponge implantation. $[^{125}I]$ -351A bound less densely to sponge stroma than to skin. We propose that AII can stimulate **angiogenesis**, acting via AT1 receptors within the sponge granuloma. AT1 and AT2 receptors and ACE develop sequentially during microvascular maturation, and the role of the endogenous angiotensin system in **angiogenesis** will depend on the balanced local expression of its various components. Pharmacol. modulation of this balance may provide novel therapeutic approaches in **angiogenesis**-dependent diseases.

ST angiotensin receptor ACE **angiogenesis**

IT Angiotensin receptors

RL: BAC (Biological activity or effector, except adverse); BPR (Biological

process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)

(AT1; sequential development of angiotensin receptors and ACE during
angiogenesis in rat s.c. sponge granuloma)

IT Angiotensin receptors

RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)

(AT2; sequential development of angiotensin receptors and ACE during
angiogenesis in rat s.c. sponge granuloma)

IT Disease, animal

(**angiogenesis**-dependent; sequential development of
angiotensin receptors and ACE during **angiogenesis** in rat s.c.
sponge granuloma in relation to treatment of **angiogenesis**
-dependent diseases)

IT **Angiogenesis**

(**neovascularization**; sequential development of angiotensin
receptors and ACE during **angiogenesis** in rat s.c. sponge
granuloma)

IT Granuloma

(sequential development of angiotensin receptors and ACE during
angiogenesis in rat s.c. sponge granuloma)

IT **Angiogenesis**

(sequential development of angiotensin receptors and ACE during
angiogenesis in rat s.c. sponge granuloma in relation to
treatment of **angiogenesis**-dependent diseases)

IT 9015-82-1, Angiotensin I converting enzyme 11128-99-7, Angiotensin II

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)

(sequential development of angiotensin receptors and ACE during
angiogenesis in rat s.c. sponge granuloma)

=> d kwic 3

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AB . . . role of angiotensin II (AII) in estrogen action on the rat
anterior pituitary gland. AII is able to enhance the
proliferation of cells isolated from estrogen-induced pituitary
tumors, as well as cells isolated from human pituitary adenomas.
Angiotensin-converting enzyme inhibitors **enalapril** and
enalprilate decreased the cell **proliferation** indexes of
DES-induced pituitary **tumors**. AII receptor blockers diminished
the d. of prolactin-immunoreactive cells in DES-induced pituitary
tumors.

=> d 3 abs

L17 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

AB A study was done to investigate the role of angiotensin II (AII) in
estrogen action on the rat anterior pituitary gland. AII is able to
enhance the **proliferation** of cells isolated from
estrogen-induced pituitary **tumors**, as well as cells isolated
from human pituitary adenomas. Angiotensin-converting enzyme inhibitors
enalapril and enalaprilate decreased the cell **proliferation**
indexes of DES-induced pituitary **tumors**. AII receptor blockers
diminished the d. of prolactin-immunoreactive cells in DES-induced
pituitary **tumors**.

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

E "LOSARTAN"/CN 25
L1 1 S E3
E "ENALAPRIL"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

L3 4684 S L1 OR L2
L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5 146 S L4 AND L3
L6 22 S L3 (L) L4
L7 3 S L6 NOT PY>2000
L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9 220 S L8 AND L3
L10 46 S L8 (L) L3
L11 18 S L10 NOT PY>2000
L12 7 S L10 AND L4
L13 7727 S LOSARTAN OR ENALAPRIL
L14 92 S L13 (L) L4
L15 28 S L14 NOT PY>2000
L16 23 S L14 NOT PY>1999
L17 4 S L16 AND L8

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	73.64	86.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.75	-3.75

FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 25 APR 2006 <20060425/UP>
MOST RECENT UPDATE WEEK: 200616 <200616/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

=> s losartan or enalapril

1362 LOSARTAN
1 LOSARTANS
1362 LOSARTAN
(LOSARTAN OR LOSARTANS)
2445 ENALAPRIL
3 ENALAPRILS
2445 ENALAPRIL
(ENALAPRIL OR ENALAPRILS)
L18 2831 LOSARTAN OR ENALAPRIL

=> s cancer? or tumor? or neoplas?
77585 CANCER?

64916 TUMOR?
22498 NEOPLAS?
L19 96710 CANCER? OR TUMOR? OR NEOPLAS?

=> s 118 and 119
L20 1575 L18 AND L19

=> s 118/clm
284 LOSARTAN/CLM
458 ENALAPRIL/CLM
L21 571 (LOSARTAN/CLM OR ENALAPRIL/CLM)

=> s 119/clm
22195 CANCER?/CLM
15078 TUMOR?/CLM
3646 NEOPLAS?/CLM
L22 31673 (CANCER?/CLM OR TUMOR?/CLM OR NEOPLAS?/CLM)

=> s 121 and 122
L23 141 L21 AND L22

=> s 123 not py>2000
592560 PY>2000
L24 15 L23 NOT PY>2000

=> s 124 not py>1999
672418 PY>1999
L25 12 L24 NOT PY>1999

=> d ibib 1-6

L25 ANSWER 1 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999043663 PCTFULL ED 20020515
TITLE (ENGLISH): N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA
DIUNSATURATED RING)CARBONYL] GUANIDINE DERIVATIVES FOR
THE TREATMENT OF ISCHEMIA
TITLE (FRENCH): DERIVES DE LA N-[(A CYCLE DI OU TRIAZA DIINSATURE
SUBSTITUE) CARBONYLE] GUANIDINE UTILISES POUR LE
TRAITEMENT DE L'ISCHEMIE
INVENTOR(S): HAMANAKA, Ernest, S.;
GUZMAN-PEREZ, Angel;
RUGGERI, Roger, B.;
WESTER, Ronald, T.;
MULARSKI, Christian, J.
PATENT ASSIGNEE(S): PFIZER PRODUCTS INC.;
HAMANAKA, Ernest, S.;
GUZMAN-PEREZ, Angel;
RUGGERI, Roger, B.;
WESTER, Ronald, T.;
MULARSKI, Christian, J.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9943663	A1	19990902

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ
TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT

APPLICATION INFO.: SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
WO 1999-IB206 A 19990205
PRIORITY INFO.: US 1998-60/076,362 19980227

L25 ANSWER 2 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999030690 PCTFULL ED 20020515
TITLE (ENGLISH): ORAL DELIVERY FORMULATION
TITLE (FRENCH): FORMULATION D'ADMINISTRATION PAR VOIE ORALE
INVENTOR(S): COMPTON, Bruce, Jon;
SOLARI, Nancy, E.;
FLANAGAN, Margaret, A.
PATENT ASSIGNEE(S): AXIA THERAPEUTICS, INC.;
COMPTON, Bruce, Jon;
SOLARI, Nancy, E.;
FLANAGAN, Margaret, A.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9930690	A1	19990624

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU
ZW GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ
TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT
SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US26627 A 19981215
PRIORITY INFO.: US 1997-60/069,501 19971215
US 1998-60/073,867 19980204
US 1998-09/055,163 19980404
US 1998-09/055,560 19980406

L25 ANSWER 3 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999018956 PCTFULL ED 20020515
TITLE (ENGLISH): 12(S)-HETE RECEPTOR BLOCKERS
TITLE (FRENCH): INHIBITEURS DU RECEPTEUR DE 12(S)-HETE
INVENTOR(S): NATARAJAN, Rama, Devi;
NADLER, Jerry, L.
PATENT ASSIGNEE(S): CITY OF HOPE
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9918956	A1	19990422

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US21570 A 19981014
PRIORITY INFO.: US 1997-60/062,335 19971015

L25 ANSWER 4 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1999008596 PCTFULL ED 20020515
TITLE (ENGLISH): MEASUREMENT OF CAPILLARY RELATED INTERSTITIAL FLUID
USING ULTRASOUND METHODS AND DEVICES

TITLE (FRENCH): MESURE DU FLUIDE INTERSTITIEL PROPRE AUX CAPILLAIRES
UTILISANT DES METHODES ET DES DISPOSITIFS
ECHOGRAPHIQUES
INVENTOR(S): LANG, Philipp;
MENDLEIN, John, D.
PATENT ASSIGNEE(S): LANG, Philipp;
MENDLEIN, John, D.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9908596	A1	19990225

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH
GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US17238 A 19980819
PRIORITY INFO.: US 1997-08/914,527 19970819

L25 ANSWER 5 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998051282 PCTFULL ED 20020514
TITLE (ENGLISH): SOLID POROUS MATRICES AND METHODS OF MAKING AND USING
THE SAME
TITLE (FRENCH): MATRICES POREUSES SOLIDES, LEUR PROCEDE DE FABRICATION
ET LEUR UTILISATION
INVENTOR(S): UNGER, Evan, C.
PATENT ASSIGNEE(S): IMARX PHARMACEUTICAL CORP.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9851282	A1	19981119

DESIGNATED STATES
W:

AU BR CA CN JP KR NZ AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1998-US9570 A 19980512
PRIORITY INFO.: US 1997-60/046,379 19970513
US 1998-9/075,477 19980511

L25 ANSWER 6 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998036784 PCTFULL ED 20020514
TITLE (ENGLISH): COATED IMPLANTABLE MEDICAL DEVICE
TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE DOTE D'UN REVETEMENT
INVENTOR(S): RAGHEB, Anthony, O.;
BATES, Brian, L.;
FEARNOT, Neal, E.;
KOZMA, Thomas, G.;
VOORHEES, William, D., III;
GERSHLICK, Anthony, H.
PATENT ASSIGNEE(S): COOK INCORPORATED
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9836784	A1	19980827

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
 KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
 CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF
 CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-US3438 A 19980220
 PRIORITY INFO.: US 1997-60/038,459 19970220

=> d kwic 2

L25 ANSWER 2 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN

CLMEN. . . a drug and the drug is selected from
 the group consisting of- isotretinoin; oxazepam; lorazepam; piroxicam;
 loperamide;
 bromopheniramine; phenylpropanolamine; loratadine; famotidine;
 ordansetron; enalapril; captopril;
 phloroglucinol; nicergoline; acetaminophen; metapimazine;
 dihydroergotamine; fexofenadine-HCl
 and albuterol.

The method of claim 24, wherein the subject is selected from the group
 consisting
 of a geriatric subject, a subject with **cancer**, a subject who
 is post-surgically recovering, a child and
 a pregnant mother.

=> d ibib 7-12

L25 ANSWER 7 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 1998032718 PCTFULL ED 20020514
 TITLE (ENGLISH): NEW FATTY ACID DERIVATIVES
 TITLE (FRENCH): NOUVEAUX DERIVES D'ACIDE GRAS
 INVENTOR(S): MYHREN, Finn;
 BORRETZEN, Bernt;
 DALEN, Are;
 SANDVOLD, Marit, Liland

PATENT ASSIGNEE(S): NORSK HYDRO ASA;
 MYHREN, Finn;
 BORRETZEN, Bernt;
 DALEN, Are;
 SANDVOLD, Marit, Liland

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9832718	A1	19980730

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH
 GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT
 BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
 CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-NO21 A 19980123
 PRIORITY INFO.: GB 1997-9701441.9 19970124

L25 ANSWER 8 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1998032022 PCTFULL ED 20020514
 TITLE (ENGLISH): GROWTH FACTOR-DEPENDENT DISEASES
 TITLE (FRENCH): MALADIES LIEES AU FACTEUR DE CROISSANCE
 INVENTOR(S): EPSTEIN, Richard, John
 PATENT ASSIGNEE(S): IMPERIAL EXPLOITATION LIMITED;
 EPSTEIN, Richard, John
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9832022	A1	19980723

DESIGNATED STATES
 W: JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1998-GB33 A 19980115
 PRIORITY INFO.: GB 1997-9700933.6 19970117

L25 ANSWER 9 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1998018610 PCTFULL ED 20020514
 TITLE (ENGLISH): EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES
 TITLE (FRENCH): INCLUSION ET ENCAPSULATION DE PARTICULES A LIBERATION CONTROLEE
 INVENTOR(S): VAN LINGERICH, Bernhard, H.
 PATENT ASSIGNEE(S): VAN LINGERICH, Bernhard, H.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9818610	A1	19980507

DESIGNATED STATES
 W: AU CA JP NO PL US AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

APPLICATION INFO.: WO 1997-US18984 A 19971027
 PRIORITY INFO.: US 1996-60/029,038 19961028
 US 1997-60/052,717 19970716

L25 ANSWER 10 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1998017331 PCTFULL ED 20020514
 TITLE (ENGLISH): SILVER IMPLANTABLE MEDICAL DEVICE
 TITLE (FRENCH): DISPOSITIF MEDICAL IMPLANTABLE ET CONTENANT DE L'ARGENT
 INVENTOR(S): BATES, Brian, L.;
 OSBORNE, Thomas, A.;
 ROBERTS, Joseph, W.;
 FEARNOT, Neal, E.;
 KOZMA, Thomas, G.;
 RAGHEB, Anthony, O.;
 VOORHEES, William, D., III
 PATENT ASSIGNEE(S): COOK INCORPORATED;
 MED INSTITUTE, INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9817331	A1	19980430

DESIGNATED STATES
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG

SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH KE LS MW SD
SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES
FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-US19188 A 19971023
PRIORITY INFO.: US 1996-60/029,158 19961024
US 1996-8/741,565 19961031
US 1997-8/803,843 19970224

L25 ANSWER 11 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1997031654 PCTFULL ED 20020514
TITLE (ENGLISH): NITRIC OXIDE DONORS CAPABLE OF REDUCING TOXICITY FROM
DRUGS
TITLE (FRENCH): DONNEURS D'OXYDE NITRIQUE CAPABLES DE DIMINUER LA
TOXICITE DE MEDICAMENTS
INVENTOR(S): DEL SOLDATO, Piero
PATENT ASSIGNEE(S): NICOX S.A.;
DEL SOLDATO, Piero
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9731654	A1	19970904

DESIGNATED STATES
W:

AL AU BB BG BR CA CN CZ EE GE HU IL IS JP KP KR LK LR
LT LV MG MK MN MX NO NZ PL RO RU SG SI SK TR TT UA US
UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT
BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1997-EP873 A 19970224
PRIORITY INFO.: IT 1996-MI96A000352 19960226

L25 ANSWER 12 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1990006775 PCTFULL ED 20020513
TITLE (ENGLISH): A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR
SUSTAINED RELEASE OF DRUGS
TITLE (FRENCH): NOUVELLE COMPOSITION DE LIPOSOMES NON PHOSPHOLIPIDIQUE
A LIBERATION SOUTENUE DE MEDICAMENTS
INVENTOR(S): RADHAKRISHNAN, Ramachandran
PATENT ASSIGNEE(S): LIPOSOME TECHNOLOGY, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 9006775	A1	19900628

DESIGNATED STATES
W:

AT AU BE CH DE DK ES FI FR GB IT JP LU NL NO SE

APPLICATION INFO.: WO 1989-US5525 A 19891206
PRIORITY INFO.: US 1988-284,158 19881214
US 1988-284,216 19881214
US 1989-Not furnished 19891201

=> d kwic 12

L25 ANSWER 12 OF 12 PCTFULL COPYRIGHT 2006 Univentio on STN

CLMEN. . . enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycin, tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycin, gentamycin, tobramycin,

piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, miconazole, apresoline, atenolol, captopril, verapamil, **enalapril**, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-

enviroxime,
ribavirin, rimantadine, amantadine, penicillin, erythromycin, tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, miconazole, apresoline, atenolol, captopril, verapamil, **enalapril**, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-

enviroxime,
ribavirin, rimantadine, amantadine, penicillin, erythromycin, tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, miconazole, apresoline, atenolol, captopril, verapamil, **enalapril**, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-

enviroxime,
ribavirin, rimantadine, amantadine, penicillin, erythromycin, F tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, miconazole, apresoline, atenolol, captopril, verapamil, **enalapril**, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-

enviroxime,
ribavirin, rimantadine, amantadine, penicillin, erythromycin, tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, miconazole, apresoline, atenolol, captopril, verapamil, **enalapril**, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-

cholesterol sulfate, 40

mole % of cholesterol and 10 mole % of the drug of Claim 25.

28a A method of suppressing **neoplastic** growth by administering to a person in need of such treatment a therapeutically effective amount of nonconventional liposome composition comprising nonphospholipid lipids and.

enviroxime,
ribavirin, rimantadine, amantadine, penicillin, erythromycin, tetracyclin, cephalothin, cefotaxime, carbenicillin, vancomycin, gentamycin, tobramycin, piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin, amikacin, amphotericin B, miconazole, apresoline, atenolol, captopril, verapamil, **enalapril**, dopamine, dextroamphetamine, pentamidine, pyribenzamine, chlorpheniramine, diphenhydramine, interferon, interleukin-

enviroxime,
ribavarin, rimantadine, amantadine, penicillin,
erythromycin, tetracyclin, cephalothin, cefotaxime,
carbenicillin, vancomycin, gentamycin, tobramycin,
piperacillin, moxalactam, cefazolin, cefadroxil, cefoxitin,
amikacin, amphotericin B, miconazole, apresoline, atenolol,
captopril, verapamil, enalapril, dopamine,
dextroamphetamine, pentamidine, pyribenzamine,
chlorpheniramine, diphenhydramine, interferon, interleukin-

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

E "LOSARTAN"/CN 25
L1 1 S E3
E "ENALAPRIL"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

L3 4684 S L1 OR L2
L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5 146 S L4 AND L3
L6 22 S L3 (L) L4
L7 3 S L6 NOT PY>2000
L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9 220 S L8 AND L3
L10 46 S L8 (L) L3
L11 18 S L10 NOT PY>2000
L12 7 S L10 AND L4
L13 7727 S LOSARTAN OR ENALAPRIL
L14 92 S L13 (L) L4
L15 28 S L14 NOT PY>2000
L16 23 S L14 NOT PY>1999
L17 4 S L16 AND L8

FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006

L18 2831 S LOSARTAN OR ENALAPRIL
L19 96710 S CANCER? OR TUMOR? OR NEOPLAS?
L20 1575 S L18 AND L19
L21 571 S L18/CLM
L22 31673 S L19/CLM
L23 141 S L21 AND L22
L24 15 S L23 NOT PY>2000
L25 12 S L24 NOT PY>1999

=> s l24 not l25

L26 3 L24 NOT L25

=> d ibib 1-3

L26 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000074742 PCTFULL ED 20020515
TITLE (ENGLISH): DEVICES AND COMPOUNDS FOR TREATING ARTERIAL RESTENOSIS
TITLE (FRENCH): DISPOSITIFS ET COMPOSES SERVANT A TRAITER LA RESTENOSE
ARTERIELLE
INVENTOR(S): ZAHRADKA, PeterRP : ADE & COMPANY
PATENT ASSIGNEE(S): CARDIO VASCULAR SOLUTIONS INC.;
ZAHRADKA, Peter
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000074742	A1	20001214

DESIGNATED STATES

W:

AE	AG	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	CA	CH	CN	CR	CU	CZ	DE	DK	DM	DZ	EE	ES	FI	GB	GD	GE	GH	GM	HR	HU	ID	IL	IN	IS	JP	KE	KG	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MA	MD	MG	MK	MN	MW	MX	MZ	NO	NZ	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL	TJ	TM	TR	TT	TZ	UA	UG	US	UZ	VN	YU	ZA	ZW	GH	GM	KE	LS	MW	MZ	SD	SL	SZ	TZ	UG	ZW	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AT	BE	CH	CY	DE	DK	ES	FI	FR	GB	GR	IE	IT	LU	MC	NL	PT	SE	BF	BJ	CF	CG	CI	CM	GA	GN	GW	ML	MR	NE	SN	TD	TG
----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----

APPLICATION INFO.:

WO 2000-CA653 A 20000601

PRIORITY INFO.:

US 1999-60/150,696 19990602

L26 ANSWER 2 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

2000040227 PCTFULL ED 20020515

TITLE (ENGLISH):

METHODS FOR TREATING CONDITIONS ASSOCIATED WITH THE
ACCUMULATION OF EXCESS EXTRACELLULAR MATRIX

TITLE (FRENCH):

PROCEDES DE TRAITEMENT D'ETATS ASSOCIES A
L'ACCUMULATION D'UN EXCEDENT DE MATRICE EXTRACELLULAIRE

INVENTOR(S):

NOBLE, Nancy, A.;
BORDER, Wayne, A.;
LAWRENCE, Daniel, A.
PATENT ASSIGNEE(S):
UNIVERSITY OF UTAH;
AMERICAN NATIONAL RED CROSS;
NOBLE, Nancy, A.;
BORDER, Wayne, A.;
LAWRENCE, Daniel, A.

LANGUAGE OF PUBL.:

English

DOCUMENT TYPE:

Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000040227	A2	20000713

DESIGNATED STATES

W:

AL	AM	AT	AU	AZ	BA	BB	BG	BR	BY	CA	CH	CN	CU	CZ	DE	DK	EE	ES	FI	GB	GD	GE	GH	GM	HR	HU	ID	IL	IN	IS	JP	KE	KG	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MD	MG	MK	MN	MW	MX	NO	NZ	PL	PT	RO	RU	SD	SE	SG	SI	SK	SL	TJ	TM	TR	TT	UA	UG	US	UZ	VN	YU	ZW	GH	GM	KE	LS	MW	SD	SL	SZ	TZ	UG	ZW	AM	AZ	BY	KG	KZ	MD	RU	TJ	TM	AT	BE	CH	CY	DE	DK	ES	FI	FR	GB	GR	IE	IT	LU	MC	NL	PT	SE	BF	BJ	CF	CG	CI	CM	GA	GN	GW	ML	MR	NE	SN	TD	TG
----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----

APPLICATION INFO.:

WO 2000-US179 A 20000105

PRIORITY INFO.:

US 1999-60/114,795 19990105

L26 ANSWER 3 OF 3

PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER:

2000001706 PCTFULL ED 20020515

TITLE (ENGLISH):

N-TERMINAL SITE SELECTIVE INHIBITORS OF HUMAN
ANGIOTENSIN CONVERSION ENZYME (ACE)

TITLE (FRENCH):

INHIBITEURS SELECTIFS DE SITE N-TERMINAL DE L'ECA

INVENTOR(S):

DIVE, Vincent;
COTTON, Joel;
CUNIASSE, Philippe;
YIOTAKIS, Athanasios;
CORVOL, Pierre;
MICHAUD, Annie;
CHAUVET, Marie-Therese;
MENARD, Joel;
EZAN, Eric

PATENT ASSIGNEE(S):

COMMISSARIAT A L'ENERGIE ATOMIQUE;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE

MEDICALE INSERM;
 DIVE, Vincent;
 COTTON, Joel;
 CUNIASSE, Philippe;
 YIOTAKIS, Athanasios;
 CORVOL, Pierre;
 MICHAUD, Annie;
 CHAUVET, Marie-Therese;
 MENARD, Joel;
 EZAN, Eric
 LANGUAGE OF PUBL.: French
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES	WO 2000001706	A1	20000113
W:	CA JP US AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC		
	NL PT SE		
APPLICATION INFO.:	WO 1999-FR1581	A	19990701
PRIORITY INFO.:	FR 1998-98/08464		19980702

=> d kwic 3

L26 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

CLMFR 10 Composition selon la revendication 8,
 dans laquelle le traitement est un traitement anti-
cancereux.

la revendication 11,
 dans laquelle le medicament est destine a reguler la
 proliferation des cellules souches hematopoietiques de
 patients soumis a un traitement anti-**cancereux.**

CH3

1 rooo)

CAPTOPRIL HS-CH2-CH - C- N - CH- COOH

il

0

COOH CH3

1 1 foee)

ENALAPRIL CH2- CH2 c N - CH-COOH

0

0

il

FOSINOPRIL]]](CH2)4 - p - CH2C CH- COOH

Uri

FI Ga 1

% D'INHIBITION DU MUTANT N-TERMINAL ACTIF. . .

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

E "LOSARTAN"/CN 25

L1 1 S E3

E "ENALAPRIL"/CN 25

L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

L3 4684 S L1 OR L2
 L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?
 L5 146 S L4 AND L3
 L6 22 S L3 (L) L4
 L7 3 S L6 NOT PY>2000
 L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
 L9 220 S L8 AND L3
 L10 46 S L8 (L) L3
 L11 18 S L10 NOT PY>2000
 L12 7 S L10 AND L4
 L13 7727 S LOSARTAN OR ENALAPRIL
 L14 92 S L13 (L) L4
 L15 28 S L14 NOT PY>2000
 L16 23 S L14 NOT PY>1999
 L17 4 S L16 AND L8

FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006

L18 2831 S LOSARTAN OR ENALAPRIL
 L19 96710 S CANCER? OR TUMOR? OR NEOPLAS?
 L20 1575 S L18 AND L19
 L21 571 S L18/CLM
 L22 31673 S L19/CLM
 L23 141 S L21 AND L22
 L24 15 S L23 NOT PY>2000
 L25 12 S L24 NOT PY>1999
 L26 3 S L24 NOT L25

=> s angiotensin II
 7881 ANGIOTENSIN
 128 ANGIOTENSINS
 7949 ANGIOTENSIN
 (ANGIOTENSIN OR ANGIOTENSINS)
 348075 II
 6036 IIS
 349694 II
 (II OR IIS)
 L27 2257 ANGIOTENSIN II
 (ANGIOTENSIN(W) II)

=> s 127/ab
 497 ANGIOTENSIN/AB
 1 ANGIOTENSINS/AB
 497 ANGIOTENSIN/AB
 ((ANGIOTENSIN OR ANGIOTENSINS)/AB)
 22147 II/AB
 18 IIS/AB
 22161 II/AB
 ((II OR IIS)/AB)
 L28 295 (ANGIOTENSIN II/AB)
 ((ANGIOTENSIN(W) II)/AB)

=> s 128 and 119
 L29 43 L28 AND L19

=> s 118 and 129
 L30 26 L18 AND L29

=> s 130 not py>2000
 592560 PY>2000
 L31 8 L30 NOT PY>2000

=> s 130 not py>1999
 672418 PY>1999

L32 6 L30 NOT PY>1999

=> d ibib 1-6

L32 ANSWER 1 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998046266 PCTFULL ED 20020514
TITLE (ENGLISH): COMPOSITIONS CONTAINING AN ANGIOTENSIN II ANTAGONIST
AND AN ANGIOTENSIN II AGONIST FOR USE IN THE TREATMENT
OF ERECTILE DYSFUNCTION
TITLE (FRENCH): COMPOSITIONS CONTENANT UN ANTAGONISTE DE L'ANGIOTENSINE
II ET UN AGONISTE DE L'ANGIOTENSINE II, DESTINEES AU
TRAITEMENT DES DYSERECTIONS
INVENTOR(S): KIFOR, Imre;
WILLIAMS, Gordon
PATENT ASSIGNEE(S): BRIGHAM & WOMEN'S HOSPITAL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9846266	A1	19981022

DESIGNATED STATES

W:

CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE

APPLICATION INFO.:

WO 1998-US5893 A 19980326

PRIORITY INFO.:

US 1997-60/041,875 19970411

L32 ANSWER 2 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998046224 PCTFULL ED 20020514
TITLE (ENGLISH): COMPOSITIONS AND METHOD FOR TREATING BLADDER
DYSFUNCTION
TITLE (FRENCH): COMPOSITIONS ET PROCEDES POUR TRAITER LE
DYSFONCTIONNEMENT DE LA VESSIE
INVENTOR(S): KIFOR, Imre;
WILLIAMS, Gordon;
SULLIVAN, Maryrose, P.
PATENT ASSIGNEE(S): BRIGHAM & WOMEN'S HOSPITAL, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9846224	A1	19981022

DESIGNATED STATES

W:

CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT
SE

APPLICATION INFO.:

WO 1998-US5886 A 19980326

PRIORITY INFO.:

US 1997-60/041,874 19970411

US 1997-60/041,875 19970411

L32 ANSWER 3 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1998018496 PCTFULL ED 20020514
TITLE (ENGLISH): CONTRAST AGENTS
TITLE (FRENCH): AGENTS DE CONTRASTE
INVENTOR(S): KLAVENESS, Jo;
NAEVESTAD, Anne;
CUTHBERTSON, Alan
PATENT ASSIGNEE(S): NYCOMED IMAGING AS;
COCKBAIN, Julian;
KLAVENESS, Jo;
NAEVESTAD, Anne;
CUTHBERTSON, Alan
LANGUAGE OF PUBL.: English

DOCUMENT TYPE:
PATENT INFORMATION:

Patent

NUMBER	KIND	DATE
WO 9818496	A2	19980507

DESIGNATED STATES
W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR
LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE
SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH KE LS
MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE
DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:
PRIORITY INFO.:

WO 1997-GB2956	A	19971028
GB 1996-9622368.0		19961028
GB 1996-9622365.6		19961028
GB 1996-9622364.9		19961028
GB 1996-9622369.8		19961028
GB 1996-9622366.4		19961028
GB 1996-9622367.2		19961028
GB 1997-9700699.3		19970115
GB 1997-9702195.0		19970204
GB 1997-9706063.6		19970324

L32 ANSWER 4 OF 6
ACCESSION NUMBER:
TITLE (ENGLISH):

PCTFULL COPYRIGHT 2006 Univentio on STN
1995029674 PCTFULL ED 20020514
A METHOD OF MODIFYING ANGIOTENSIN RECEPTOR ACTIVITY FOR
TREATMENT OF PREMENSTRUAL SYNDROME AND MEDIATION OF
PAIN

TITLE (FRENCH):

METHODE DE MODIFICATION DE L'ACTIVITE DU RECEPTEUR DE
L'ANGIOTENSINE POUR LE TRAITEMENT DU SYNDROME
PREMENSTRUEL ET DE LA DOULEUR

INVENTOR(S):
PATENT ASSIGNEE(S):
LANGUAGE OF PUBL.:
DOCUMENT TYPE:
PATENT INFORMATION:

DePADOVA, Anthony, S.
DePADOVA, Anthony, S.
English
Patent

NUMBER	KIND	DATE
WO 9529674	A1	19951109

DESIGNATED STATES
W:

AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU
JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NO NZ PL PT
RO RU SD SE SI SK TJ TT UA US UZ VN KE MW SD SZ UG AT
BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF
CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.:
PRIORITY INFO.:

WO 1995-US5312	A	19950428
US 1994-8/235,468		19940429

L32 ANSWER 5 OF 6
ACCESSION NUMBER:
TITLE (ENGLISH):
TITLE (FRENCH):
INVENTOR(S):

PCTFULL COPYRIGHT 2006 Univentio on STN
1995006410 PCTFULL ED 20020514
ANTAGONIST OF ANGIOTENSIN II RECEPTORS
ANTAGONISTE DES RECEPTEURS DE L'ANGIOTENSINE II
GRISWOLD, Don, Edgar;

PATENT ASSIGNEE(S):

WHARTON, John
SMITHKLINE BEECHAM CORPORATION;
GRISWOLD, Don, Edgar;
WHARTON, John

DOCUMENT TYPE:
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9506410	A1	19950309

DESIGNATED STATES

W:

AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ LK MG MN MW
 NO NZ PL RO RU SD SI SK UA US VN AT BE CH DE DK ES FR
 GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
 MR NE SN TD TG

APPLICATION INFO.: WO 1994-US10258 A 19940901
 PRIORITY INFO.: US 1993-8/115,968 19930901

L32 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1992020661 PCTFULL ED 20020513
 TITLE (ENGLISH): N, N-DIACYLPIPERAZINES
 TITLE (FRENCH): N, N-DIACYLPIPERAZINES
 INVENTOR(S): ASHTON, Wallace, T.;
 GREENLEE, William, J.;
 WU, Mu, Tsu;
 DORN, Conrad, P.;
 MacCOSS, Malcolm;
 MILLS, Sander, G.
 PATENT ASSIGNEE(S): MERCK & CO., INC.
 LANGUAGE OF PUBL.: English
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9220661	A1	19921126

DESIGNATED STATES

W:

AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE

APPLICATION INFO.: WO 1992-US4189 A 19920519
 PRIORITY INFO.: US 1991-703,953 19910522
 US 1992-885,416 19920519

=> d kwic 5

L32 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ABEN The present invention relates to the use of an **angiotensin**
 II receptor antagonist in the
 manufacture of a medicament for the treatment of chronic inflammatory
 disease states.

DETD . . . for
 angiotensin in the regulation of tissue injury,
 proliferation and differen-tiation. As such this would
 include treatment of disorders such as **tumor** growth, i.e.
neoplastic transformation and growth/metasis, bone marrow
 maturation and differen-tiation, skin maturation and
 differentiation, and hepatocyte maturation and
 differentiation. Chronic inflammatory diseases would. . .

Vol. 183, pp 989-995 (1992), and is a member of the
 superfamily of G protein-coupled transmembrane receptors.
 AT1 antagonists such as **losartan** (Whitebread et al., supra)
 al., J. Med. Chem., Vol. 34, pp 1514-1517 (1991),
 sensitivity to reducing agents such as dithiothreitol
 (DTT) (Whitebread et. . .

published January 20, 1988. Preferred compounds
 included within this class of All receptor antagonists are
 (hydroxymethyl)-imidazole (also referred to as **Losartan**
 herein); or a pharmaceutically acceptable salt thereof

µM PD123319 (AT1 receptors remain unblocked) or with 10 µM
 µM PD123319 (AT1 receptors remain unblocked) or with 10 µM

losartan (AT2 receptors remain unblocked). Guanine nucleotide sensitivity of AII binding was assessed by coincubating sections with 0.25 nM [¹²⁵I]AII and 1. . .

Losartan was kindly provided by DuPont Merck, Wilmington, SmithKline Beecham, King of Prussia, PA, U.S.A., and PD123319 by Parke-Davis, Ann Arbor, MI, . . .

with osteoarthritis and those with rheumatoid arthritis, specific ([¹²⁵I](Sar1, Ile8)AII binding to each structure was completely inhibited by the AT1 antagonist **losartan** (10 μM), but was not significantly inhibited by the specific AT2 antagonist PD123319 (10 μM) (table 6) . Specific binding to. . .

163, pp 264- 291 (1989); Weinstock et al., J. Med. Chem., Vol. 34, 1514-1517 (1991). Binding studies performed in the presence of

losartan or PD123319 provide no evidence for the presence of AT2 receptors in synovium from any of these disease groups. The data. . .

enzyme inhibitors are listed. No patient had received glucocorticosteroids within the month prior to surgery. Abbreviations; AZA; azathioprine, CC; chondrocalcinosis, ENA; **enalapril**, MTX; methotrexate, OA; osteoarthritis, RA; rheumatoid arthritis, SZ; sulphasalazine

2.00) c 3.39 (2.19 to 5.25)

Al

Al d 12.6 (6.6 to 24.6) d 8.32 (4.17 to 16.2) d 15.1 (7.41 to 31.6)

Losartan e 37.2 (15.9 to 87.1) e 102.3 (33.1 to 316.2)e 75.9 (32.4 to 177.8

1-(4carboxyphenyl)-methyl)-1 H-imidazol-

5-yl]-2(2-thienyl)-

PD 123319. . . 10,000

nHill val=

(Sar1, Ile8) 1.0(0.8 to 1.3) 1.2(0.9 to 1.6) 1.6(1.2 to 2.0)

All

All 1.0(0.6 to 1.5) 0.9(0.5 to 1.2) 0.8(0.5 to 1.2)

Losartan 0.6(0.4 to 0.8) 0.9(0.5 to 1.2)

0.6(0.3 to 0.8)

1-(4carboxyphenyl)-

methyl)-1H-

(2-thienyl)methyl-

2-propenoic acid

PD 123319

Footnotes to Table 5:

a. . . c (Sar1, Ile8) All was significantly more potent than All (each p lt; 0.05), d All was significantly more potent than **losartan** in lining cells 2-propenoic acid in all structures (each p lt; 0.05). e no significant differences were observed in Ki. . .

Effect of the specific AT1 antagonist **Losartan** and AT2 antagonist PD 123319 on binding of [¹²⁵I] (Sar1, Ile8) angiotensin II bindin to human s novium

Total	Nonspecific	Losartan
PD123319		
Blood Vessels	O A 7.9 (6.0 to 10)	2.4 (2.2 to 2.6)
a 2.9 (2.4 to 3.5)	b 7.1 (5.1 . . . 2.6	
R A 3.0 (2.3 to 4.0)	1.6 (1.5 to 1.7)	a 1.5 (1.5 to 1.6)
b 2.9 (2.1 to 4.1		
a Losartan (10 µM) significantly inhibits binding to each		
structure in synovium from patients with osteoarthritis (OA)		
or rheumatoid arthritis (RA) (each. . .		

=> d ibib kwic 5-6

L32 ANSWER 5 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN
 ACCESSION NUMBER: 1995006410 PCTFULL ED 20020514
 TITLE (ENGLISH): ANTAGONIST OF ANGIOTENSIN II RECEPTORS
 TITLE (FRENCH): ANTAGONISTE DES RECEPTEURS DE L'ANGIOTENSINE II
 INVENTOR(S): GRISWOLD, Don, Edgar;
 WHARTON, John
 PATENT ASSIGNEE(S): SMITHKLINE BEECHAM CORPORATION;
 GRISWOLD, Don, Edgar;
 WHARTON, John
 DOCUMENT TYPE: Patent
 PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9506410	A1	19950309

DESIGNATED STATES

W: AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ LK MG MN MW
 NO NZ PL RO RU SD SI SK UA US VN AT BE CH DE DK ES FR
 GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML
 MR NE SN TD TG

APPLICATION INFO.: WO 1994-US10258 A 19940901
 PRIORITY INFO.: US 1993-8/115,968 19930901

ABEN The present invention relates to the use of an **angiotensin II** receptor antagonist in the manufacture of a medicament for the treatment of chronic inflammatory disease states.

DETD . . . for
 angiotensin in the regulation of tissue injury, proliferation and differen-tiation. As such this would include treatment of disorders such as **tumor** growth, i.e. **neoplastic** transformation and growth/metasis, bone marrow maturation and differen-tiation, skin maturation and differentiation, and hepatocyte maturation and differentiation. Chronic inflammatory diseases would. . .

Vol. 183, pp 989-995 (1992), and is a member of the superfamily of G protein-coupled transmembrane receptors. AT1 antagonists such as **losartan** (Whitebread et al., supra) al., J. Med. Chem., Vol. 34, pp 1514-1517 (1991), sensitivity to reducing agents such as dithiothreitol (DTT) (Whitebread et. . .

published January 20, 1988. Preferred compounds included within this class of All receptor antagonists are (hydroxymethyl)-imidazole (also referred to as **Losartan** herein); or a pharmaceutically acceptable salt thereof

µM PD123319 (AT1 receptors remain unblocked) or with 10 µM
 µM PD123319 (AT1 receptors remain unblocked) or with 10 µM

losartan (AT2 receptors remain unblocked). Guanine nucleotide sensitivity of AII binding was assessed by coincubating sections with 0.25 nM [¹²⁵I]AII and 1. . .

Losartan was kindly provided by DuPont Merck, Wilmington, SmithKline Beecham, King of Prussia, PA, U.S.A., and PD123319 by Parke-Davis, Ann Arbor, MI, . . .

with osteoarthritis and those with rheumatoid arthritis, specific ([¹²⁵I](Sar1, Ile8)AII binding to each structure was completely inhibited by the AT1 antagonist losartan (10 μM), but was not significantly inhibited by the specific AT2 antagonist PD123319 (10 μM) (table 6). Specific binding to. . .

163, pp 264- 291 (1989); Weinstock et al., J. Med. Chem., Vol. 34, 1514-1517 (1991). Binding studies performed in the presence of

losartan or PD123319 provide no evidence for the presence of AT2 receptors in synovium from any of these disease groups. The data. . .

enzyme inhibitors are listed. No patient had received glucocorticosteroids within the month prior to surgery. Abbreviations; AZA; azathioprine, CC; chondrocalcinosis, ENA; enalapril, MTX; methotrexate, OA; osteoarthritis, RA; rheumatoid arthritis, SZ; sulphasalazine

2.00) c 3.39 (2.19 to 5.25)

Al

Al d 12.6 (6.6 to 24.6) d 8.32 (4.17 to 16.2) d 15.1 (7.41 to 31.6)

Losartan e 37.2 (15.9 to 87.1) e 102.3 (33.1 to 316.2)e 75.9 (32.4 to 177.8

1-(4carboxyphenyl)-methyl)-1 H-imidazol-

5-yl]-2(2-thienyl)-

PD 123319. . . 10,000

nHill val=

(Sar1, Ile8) 1.0(0.8 to 1.3) 1.2(0.9 to 1.6) 1.6(1.2 to 2.0)

All

All 1.0(0.6 to 1.5) 0.9(0.5 to 1.2) 0.8(0.5 to 1.2)

Losartan 0.6(0.4 to 0.8) 0.9(0.5 to 1.2)

0.6(0.3 to 0.8)

1-(4carboxyphenyl)-

methyl)-1H-

(2-thienyl)methyl-

2-propenoic acid

PD 123319

Footnotes to Table 5:

a. . . c (Sar1, Ile8) All was significantly more potent than All (each p lt; 0.05), d All was significantly more potent than losartan in lining cells 2-propenoic acid in all structures (each p lt; 0.05). e no significant differences were observed in Ki. . .

Effect of the specific AT1 antagonist Losartan and AT2 antagonist PD 123319 on binding of [¹²⁵I] (Sar1, Ile8) angiotensin II bindin to human s novium

Total	Nonspecific	Losartan
PD123319		
Blood Vessels	O A	7.9 (6.0 to 10)
a 2.9 (2.4 to 3.5)	b 7.1 (5.1 . . . 2.6	2.4 (2.2 to 2.6)
R A	3.0 (2.3 to 4.0)	1.6 (1.5 to 1.7)
b 2.9 (2.1 to 4.1		a 1.5 (1.5 to 1.6)

a **Losartan** (10 µM) significantly inhibits binding to each structure in synovium from patients with osteoarthritis (OA) or rheumatoid arthritis (RA) (each. . . .

L32 ANSWER 6 OF 6 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 1992020661 PCTFULL ED 20020513

TITLE (ENGLISH): N, N-DIACYLPIPERAZINES

TITLE (FRENCH): N, N-DIACYLPIPERAZINES

INVENTOR(S): ASHTON, Wallace, T.;
GREENLEE, William, J.;

WU, Mu, Tsu;

DORN, Conrad, P.;

MacCOSS, Malcolm;

MILLS, Sander, G.

PATENT ASSIGNEE(S): MERCK & CO., INC.

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
--------	------	------

WO 9220661	A1	19921126
------------	----	----------

DESIGNATED STATES

W:

AT BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE

APPLICATION INFO.: WO 1992-US4189 A 19920519

PRIORITY INFO.: US 1991-703,953 19910522

US 1992-885,416 19920519

ABEN Diacylpiperazines of general structure (I) are: **angiotensin**

II (A-II) antagonists selective for the type 2 (AT2) subtype useful in the treatment of cerebrovascular, cognitive, and CNS disorders; tachykinin. . . .

DETD . . . processes leading to ovulation has been reviewed (Andrade-Gordon, et al. Biochem, Pharmacol., 42, 715-719 (1991)),
1 5

In addition, AT2 receptors are found in neuronal **tumor** cells (Speth, et al, Peptide Res,, 2, 232-239 (1989)) and in transformed human neural cells (Tallant, et al, Llypertension, 17, 1135-1143 (1991)).

of angiotensin II to

AT2 receptors in reproductive organs. The compounds of the present invention are also useful as anticancer agents for brain **cancers** and other **cancers** wherein the AT2 receptor is prevelant,

SUBSTANCE P ANTAGONISM ASSAY

The compounds of this invention are useful for antagonizing substance P in the treatment. . . .

to

the hypertensive eye in solution in a suitable ophthalmic vehicle, Also, these compounds may be useful in the reversal of multidrug resistance in **tumor** cells by enhancing the efficacy -of chemotherapeutic agents. In add ition, these

compounds may have activity in blocking calcium channels in insect brain. . .

These include acetylcholinesterase inhibitors such as heptylphosphostigmine and tetrahydroacridine (THA; tacrine), muscarinic agonists such as oxotremorine, inhibitors of angiotensin-converting enzyme such as octylramipril, captopril, ceranapril, **enalapril**, lisinopril, fosinopril and zofenopril, centrally-acting calcium channel blockers and as nimodipine, and nootropic agents such as piracetam.

CLMEN 22 A method for inhibiting the growth of neruonal **tumor** cells which contain AT2 receptors in a patient in need thereof which comprises the administration to the patient of an effective amount of. . .

35 A method for the treatment of multidrug resistant **tumor** cells comprising the administration to a mammal in need of such treatment of an effective amount of the compound of Claim 1,

=> d his

(FILE 'HOME' ENTERED AT 10:11:24 ON 26 APR 2006)

FILE 'REGISTRY' ENTERED AT 10:11:33 ON 26 APR 2006

E "LOSARTAN"/CN 25
L1 1 S E3
E "ENALAPRIL"/CN 25
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 10:12:56 ON 26 APR 2006

L3 4684 S L1 OR L2
L4 704495 S CANCER? OR TUMOR? OR NEOPLAS?
L5 146 S L4 AND L3
L6 22 S L3 (L) L4
L7 3 S L6 NOT PY>2000
L8 266785 S PROLIF? OR ANGIOGEN? OR NEOVASCULAR?
L9 220 S L8 AND L3
L10 46 S L8 (L) L3
L11 18 S L10 NOT PY>2000
L12 7 S L10 AND L4
L13 7727 S LOSARTAN OR ENALAPRIL
L14 92 S L13 (L) L4
L15 28 S L14 NOT PY>2000
L16 23 S L14 NOT PY>1999
L17 4 S L16 AND L8

FILE 'PCTFULL' ENTERED AT 10:25:28 ON 26 APR 2006

L18 2831 S LOSARTAN OR ENALAPRIL
L19 96710 S CANCER? OR TUMOR? OR NEOPLAS?
L20 1575 S L18 AND L19
L21 571 S L18/CLM
L22 31673 S L19/CLM
L23 141 S L21 AND L22
L24 15 S L23 NOT PY>2000
L25 12 S L24 NOT PY>1999
L26 3 S L24 NOT L25
L27 2257 S ANGIOTENSIN II
L28 295 S L27/AB

L29	43 S L28 AND L19
L30	26 S L18 AND L29
L31	8 S L30 NOT PY>2000
L32	6 S L30 NOT PY>1999